For the first edition of the prestige seminars organized by our BRIC unit, we are delighted to welcome Dr Olivier Delattre, Research Director at Curie Institute, head of the Unit U830 \u201cCancer, Heterogeneity, Instability and Plasticity\u201d (CHIP) and \u201cGrand prix INSERM 2022\u201d<\/p>\n
We will take advantage of his visit to organize meetings with researchers and students from our unit.<\/p>\n
Seminar at 5pm on Tuesday February 6, 2024, BBS conference room, 2 rue Dr Hoffmann Martinot.<\/p>\n
Dr. Olivier Delattre is MD-PhD, trained in pediatric oncology. He is Research Director at Inserm and heads the Research Unit U830 \u201cCancer, Heterogeneity, Instability and Plasticity\u201d (CHIP) and the research team \u201cDiversity and plasticity of children tumours\u201d (DePiCT) at the Institut Curie (Paris). He has also created the Somatic Genetics Unit, aimed to transfer research results to the clinic, and heads the \u201cGenetic and Biology of Cancer\u201d department at the Institut Curie. He also leads the SIREDO Center (Care, Innovation, Research in Oncology of Children, Adolescent and Young Adults) at the Institut Curie, gathering clinicians and researchers to accelerate the development of new therapeutic strategies for pediatric cancers. His lab identified some key genetic alterations in Ewing sarcoma, rhabdoid tumors, neuroblastoma as well as in various sarcomas, and also the Neurofibromatosis type 2 (NF2<\/em>) tumour suppressor gene. His lab investigates the functional consequences of these alterations in tumour development, and has established cellular and animal models. His current fields of interest are the study of genetic alterations associated with pediatric cancers, the study of pediatric cancers cells-of-origin and the mechanisms of cancer cells phenotypic plasticity. Dr Delattre has published more than 400 papers, many of them in the most prestigious journals such as Nature<\/em>, Nature Genetics<\/em>, Nature Medicine<\/em>, Cancer Cell<\/em>, Molecular Cell<\/em>, New England Journal of Medicine<\/em>\u2026, with an H-index of 102. He received numerous awards including the \u201cAssociation pour la Recherche sur le Cancer (ARC)-Leopold Griffuel\u201d award in 2016, the \u201cGrand Prix de la Recherche Inserm\u201d in 2022, and the \u201cAmerican Association for Cancer Research (AACR)-St. Baldrick\u2019s Foundation\u201d Award for Outstanding Achievement in Pediatric Cancer Research in 2023. He is an elected member of EMBO (European Molecular Biology Organization). <\/p>\n \ud83c\udfa4 Ewing sarcoma: From genetics to epigenetics and immunology.<\/strong><\/em><\/span><\/p>\n Ewing sarcoma is a bone cancer mostly observed in children and young adults. The EWSR1::FLI1<\/em> gene fusion (Nature<\/em> 1992) is a key driver of this malignancy ( J. Clin. Oncol. <\/em> 1996, 2010; Cancer Discov.<\/em> 2014). It completely reprograms the Ewing cell-of-origin (Cancer Cell<\/em> 2007; Cancer Res.<\/em> 2021) through direct binding at GGAA microsatellites and subsequent transformation of these sequences into bona fide<\/em> enhancers (PLoS One<\/em> 2009; Nature Genetics<\/em> 2015; Nature Medicine <\/em>2017; Nat Rev Dis Primers<\/em> 2018). Activation of GGAA microsatellites also leads to specific transcription of intergenic regions (Cancer Cell<\/em> 2021, 2022; Mol Cell<\/em>, 2022; Cell Rep.<\/em> 2022). Recent data of the laboratory indicate that some of these transcripts can be translated thus leading to important applications for immunotherapy. <\/span><\/p>\n <\/p>\n